Cancer vaccines for established cancer: how to make them better?
about
Tumor cell lysates as immunogenic sources for cancer vaccine designThe transcription factor RBP-J-mediated signaling is essential for dendritic cells to evoke efficient anti-tumor immune responses in mice.Natural splice variant of MHC class I cytoplasmic tail enhances dendritic cell-induced CD8+ T-cell responses and boosts anti-tumor immunity.siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice.Nanoparticle-delivered transforming growth factor-β siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment.Dendritic cell subsets as vectors and targets for improved cancer therapyDeveloping an effective breast cancer vaccine.Dendritic cells: are they clinically relevant?Guiding the "misguided" - functional conditioning of dendritic cells for the DC-based immunotherapy against tumours.Potential clinical applications for human pluripotent stem cell-derived blood components.Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system.Shaping of NK cell responses by the tumor microenvironmentThe role of Toll-like receptor 4 polymorphisms in vaccine immune response.Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells.Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1, CEA, and a triad of costimulatory molecules (rF-PANVAC).Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: profile comparison.Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas.
P2860
Q28083469-E16042AD-2AB7-42BC-BC59-82C83FBE573AQ33842422-06D20D6D-08BD-4E39-B07B-03E53184404CQ34000832-A22C3E2D-1674-446B-9318-79B06918F64AQ35546869-FD394982-33C9-409F-9816-E7A47AAA3FA9Q37731681-0801AA3D-16C5-4B2D-9245-6FBC0FFD620FQ37758502-4EB36A01-1E36-4B02-A6D6-8D25F3E7A2BFQ37776145-3FF2C15A-FFB2-4E6A-AC80-123477B6FBBAQ37778692-70832F38-693E-439D-9624-71F3DD53C5DAQ37823518-BA6D6142-FEB9-42A5-9F16-04D0D1FC703FQ37857709-50554AFE-57BC-4B3F-B0AB-63E1B69117E0Q38031222-9389182B-32D1-4F9E-8B63-B4A93E619F34Q38067641-099877B1-AC53-4767-A2C1-5938B7D7C844Q38396207-052C4B48-B5BF-487D-BC4A-122DE412E699Q40952120-3FBC4B3C-0450-4F6B-838B-459E7BD3187FQ42089413-25C14D18-41EB-4A95-AA3F-D148A74EA552Q43859473-313AC907-A97C-4D11-B339-9E8E29917B27Q45988106-2B3D68AB-E837-4D83-8010-75C8ED7B0721
P2860
Cancer vaccines for established cancer: how to make them better?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cancer vaccines for established cancer: how to make them better?
@en
Cancer vaccines for established cancer: how to make them better?
@nl
type
label
Cancer vaccines for established cancer: how to make them better?
@en
Cancer vaccines for established cancer: how to make them better?
@nl
prefLabel
Cancer vaccines for established cancer: how to make them better?
@en
Cancer vaccines for established cancer: how to make them better?
@nl
P2860
P1476
Cancer vaccines for established cancer: how to make them better?
@en
P2093
Daniel M Andrews
Eugene Maraskovsky
P2860
P304
P356
10.1111/J.1600-065X.2008.00612.X
P577
2008-04-01T00:00:00Z